Peptides Cut Mortality In HALF! Why Doctors Are Hiding This Longevity Secret l Ep #394

[music] Hi, I'm Natalie Nidham, your host. Today I'm joined once again by Dr. Bill Lawrence, a longevity researcher whose past episodes are still some of the most downloaded on this show. And that's because so many of us are united in our fascination with his main topic, which are bio-regulator peptides.

Now, Bill trained directly with Professor Cavvenson, the Russian scientist who discovered and researched bioregulator peptides and ran extensive human clinical trials in Russia where certain peptides cut mortality almost in half. Actually, in some studies, more than half. Now, in this episode, Bill finally shares the long-awaited data from his 8-year tie study and 5-year epigenetic age study. We talk about what actually happened to real people's biological age, organ level aging, and why the pineal and thymus peptides seem to punch so far above their weight.

This episode is brought to you by the Kinon Move Plus red light and infrared light device, Beam Minerals, and Neutropept from LevelUp Health. All with special offers just for you. Just go to the show notes below for details. Now, enjoy the show.

Dr. Bill Lawrence, we are finally back again. This is an interview that I've been looking forward to for a very long time. Thank you so much for taking time out of your schedule for this.

It's my pleasure always, Natalie.

Well, we have we have a bit of a history together. Guys, in the show notes, you will find links to the first three episodes that we recorded together. I think those first two episodes we recorded together to this day are probably the most downloaded episodes that I've ever recorded on this podcast. So, you get to you hold the prize for the episodes that blew people's minds the most. And there's a lot of mind-blowing stuff on this podcast. I just want to say thank you for the work that you do. I mean obviously what we're talking about today is biorereggulator peptides and so much of what gets discussed on biorereggulators is you know there's a lot of theory out there too often and I find this even in the medical field people disregard a lot of the foundational research that was done on the bio regulators and so you know maybe maybe just to set the stage for what we're going to present today which is really for people who've been f following bio-regulators this is the moment we've kind of all been waiting for right this is the culmination of eight years of kind of field clinical research that you've been conducting in this space can we just set the stage a little bit for people in terms of the bio regulators and your interactions with Dr. Cavson who really is the man that kind of started this whole thing like he is the he's the papa in the world of biorulated peptides who we all look up to or did.

Yeah. I I I think I can give you a real quick summary of of both the history of it um and then my involvement and my relationship with Professor Kevinson. Um where this all started was during the Cold War. Um, the Russians became aware that the American military was developing certain weapons that would have [snorts] the ability to damage vision, hearing, and so forth. And I'm [clears throat] sure the the uh Soviet Union, you know, was working on similar kinds of things. And the other thing that was happening was that [snorts] uh the they were the Soviet Union uh Navy was uh noticing that sending out these uh submarines with you know young submariners I guess they call them uh sitting in a submarine that was built in the late 50s and early 60s with a nuclear reactor that was primitive didn't have you know top rate protection irradiation protections over they would come back after being on on [clears throat] these voyages with all sorts of medical issues, primarily uh thymus destruction uh issues and so forth, immune system um is was you know just a mess. And so they realized that they couldn't have this situation developing. So they took uh a group of military doctors and scientists of which uh professor Cavinson was both. has an MD and a PhD and said, "You've got to solve this problem. Um, we've we've got to have protection on the battlefield if these lasers that the Americans are working on come to be, and we've got to have uh the submarines, you know, come back with healthy sailors and so forth. And we're also concerned about our cosminaut program, what's going to happen when they come back?" Uh, cosminaut program is their term for the astronaut program. So according to professor cavenson the Soviet Union just threw enormous amounts of money. It was basically a blank check uh which in the world of science is just a wonderful you know situation to be in. And they um they went back and did research starting with Ivan Pavlof back in the the early 1900s and they realized that um when food breaks down into amino acids uh it you know passes through the digestive system and so forth. But if you can break down into what we call peptides rather than the proteins that most of it ends up being that you found you could find yourself in a um a whole different world using uh peptides as um substances that had dramatic regeneration uh properties. And what they discovered was that if you create very short little amino acids, peptides, little strings of two, three and four and so forth primarily that the amino acids or the peptides passed through membranes, uh the arterial system, even the bloodb brain barrier and so forth. And what was mostly interesting is that where you sourced the peptides from, which in this case were animals, they were pigs and and cows, that when you took a portion of that animal and you selected a specific um organ like you selected the heart or the liver, kidney and so forth, and you broke it down into these short chain amino acids that when a human being had that introduced into the body, the liver peptides or the kidney peptides, they didn't just float around generally. They went to the liver, to the kidney, to the brain and so forth. In other words, they were organ specific. There were receptors on those organs that recognized these short- chain amino acids. And um so when they started using them very quickly, the submarine issues went away. the the they they uh administered the peptides to the submarine people before they were going out on these um trainings and so forth. They gave them to the cat and they gave them to them also when they came back. They gave them to the cosminauts and so forth. And so that's where this started and they only had two peptides to start with. They had a pineal gland peptide and they had a thymus peptide. But just using those two, they were able to get protective by through regeneration, they were able to get into a protective uh situation with the sailors and so forth, the cosminauts. And then they used them for the uh Olympic teams for recovery and so forth. And then um as as they realized how potent those two peptides were, they started to expand and they took different organs out of these animals and they ended up with basically 21 or 22 depending on how you count one of the peptides. They've now have 21 or 22 of these what we call natural extract peptides. All of them organ specific. So they have you know pep peptide for the pancreas uh peptide for res restoration of cartilage and so forth and so forth.

And so what professor cavson did was he started doing longevity studies or at least mortality reduction studies uh in the late 1990s and we're going to show some of those in the in the slides here in a moment and I'll talk more specifically about them. But what they found was that not only could they do organ regeneration but they could actually reduce mortality by huge huge percentages and I'll go into the slides. So that's sort of the background and um professor Cson has extremely well known in Europe. Everybody in Europe knows him and he's been the head of this and that you know society and institutes and so forth. Basically his biography is crazy.

Yeah. Yeah. I I think the last count that I was aware of, he had se over 700 articles and clinical studies published. Anyway, um I got involved because at some point in my life, I decided to stop making money so much and focus on staying alive. um without going into the history, my family just doesn't for the men don't doesn't have a very long good longevity uh history and my father had died early and I thought I better do something uh take a different direction and so uh went to school got the PhD I had a law degree and a master's and bunch of other stuff got the PhD and decided to focus on longevity for obvious very selfish reasons and I ran across um when when uh Google translator became available. I started running, you know, at looking at studies that came from all over the world because up to that time, you could only really look at studies from the United States, Britain, Israel, and so forth. Very restrictive. But now the whole world opened up and I came across um a published study that I'm going to show you the results of in a few moments. uh where professor Cavenson was able to reduce mortality over periods of 6 8 10 12 years by 60 70%. I mean it was just astounding. It was so it was so astounding that I thought this can't be for real. But I dug into the data and so forth and realized it was for real. And unlike America where you have to be very careful when you're looking at a pharmaceutical clinical study, u there's a a lot of manipulation of the data. In fact, when I got my PhD, the first five years, I basically was a consultant to uh medical clinics uh to analyze the pharmaceutical clinical studies and tell them the real reality of those studies rather than the pharmaceutical sort of advertising that they do. Anyway, so I read these studies and um contacted the institute in St. Petersburg and said, I want to come over there and see what you guys are doing. And to my surprise, they said, um, yes, you know, we'd be happy to have you. And so, uh, Vess and I, this is like 12 years ago or something like that. We went to Russia to St. Petersburg. And I think that Professor Cabinson and the staff there, I mean, they were gracious as could be. I think they were so surprised and literally stunned. you got on a plane [laughter] that you know I wouldn't consider myself a scientist at that point but certainly I was a researcher would would be so interested in their work and so they literally took us in uh and that was 10 or 12 years ago and uh after I'd worked with them for a couple of years and understood the peptides and so forth uh Cavinson and I talked about let's let's do an American study you know we have all these studies here in Russia let's do a study in America um and duplicate some I call it a confirming study. Uh duplicate what you've done here in Russia. Um and let's do it as a longevity study because I'm not a doctor so I can't I can't be you know repairing kidneys and livers and so forth even though the peptides would actually do that and indirectly we actually sort of do that. Um so we decided to put together this clinical study and what I'm going to talk about today and show in the slides is the results of eight years of that study for tieumirs and about five years epigenetics. Those two biomarkers are primary biological age markers. And so people sometimes I think they get confused. It's not it's not possible to have an accurate biological age for a human being. Um, it's the system is too complex. I mean human systems are so complex that you cannot have one number that represents. What's interesting is that we've gone and I'll talk about this with some of the slides. We've gone from having just a one number where we're now able to break down different [clears throat] systems and organs and determine a and I don't like the term biological age but it's something people can understand. We can determine the biological age of about 19 different organs as well as the overall system. So we started our study uh using tieumirs which I'll explain briefly when we get to a slide and then after that epigenetics which is about gene uh modification and we've gotten outstanding results and I'm going to share with everybody those results today.

[music] Hey folks, I just wanted to take a quick minute to tell you about something that I've created just for you guys, my listeners. I've created an amazing holiday gift guide for listeners so that you can get the best Black Friday deals on biohacking tools, supplements, and so much more. There are gifts in different price ranges and once a year price drops on your dream health tech. And no one said you can't shop for yourself, so you can get the stuff for friends and family or for yourself. All you've got to do is go to natnit.com/giftguide for the list of Black Friday deals that you just can't miss. That's a beautiful summary of really what what those first couple of episodes were about. So, if people are interested in getting into the details on some of that stuff, then definitely go back to those episodes and come back to, you know, if you don't want to read the end of the book before the beginning of the book, go back to the beginning of the book. [laughter] Yeah. Cuz this is this isn't the end of the book, but this is definitely the next level. Right. We've all been we've all been waiting for these results with baited breath. And as you mentioned, like this is building on a lot of the clinical studies that Professor Kevinson did run in Russia. There was there's the, you know, I always laugh when I use these terms because these are straight off the paper. The old people study, the elderly people study. There's the gasp prom study which is was was conducted in a factory in Siberia. And what's notable about all of those studies, which you've replicated in your work, is that people were not asked to change anything else. They were not asked to change their diet. They were not asked to change their lifestyle. Whether they did on their own or they didn't is is not even the point. The point really was to identify what impact could these tiny proteins t called biorereggulator peptides have on a person's mortality rate and and it was you know I think you made this point also earlier was that people live too long to do a longevity study so we do a can we prevent people from dying sooner bottom line is kind of what boils down to um I think one of the things that that I I found really interesting when I was reading a lot of the earlier work was when he was talking about food and please correct me if I'm wrong here but I think one of the things he described is that these sequences of peptides these little bio-regulator peptides they kind of they're embedded in the proteins in food and they have they have cleavage sites that are very specific that allow them to be to remain intact so that when they get transported out of the gut into the body, you have a this little peptide that's kind of going to find its way to the target organ. Is that is that about right? Because that's that was one of the things that was so fascinating to me is that they exist in food.

Yeah, that is ab absolutely correct. I sometimes will use the metaphor of the uh because I lived in Alaska for a long time, the salmon, you know, the the salmon uh will uh depart from, you know, where they were basically hatched and so forth. And they'll go out spending, you know, four or five years in in the oceans and so forth. And then with thousands of creeks and rivers and so forth to choose from, they all go back to where they were originally born or or conceived, you might say, and so forth.

We call them cleavage sites. We I sometimes refer to them as docking sites. That is the amino acids will swim through the arterial system, pass through the membranes, and they're looking for the liver and they're looking for the receptacles on the liver and that's what allows these peptide bio regulators at literally at the cellular level. Um people talk about cellular reprogramming. There's a lot of information thrown around. Unfortunately, not very much proof yet. Um but that's the concept is that these amino acids are cellular reprogramming substances that then result in tissue rejuvenation and then finally organ regeneration. Uh oh yeah you've got you've got it down and I think I got this from you. I will refer to bio regulators often as the ultimate epigenetic switches because they have they are actually able to influence the way that that our DNA expresses. And you had said in our last interview together that your hypothesis, which may still be a hypothesis or you may have proved it since then, is that what they're actually doing is correcting the expression of the DNA or resetting it back to a more youthful setting. So that, you know, just as we used to heal on the go as young children, as we age, we we lose that capacity. And maybe it's restoring at least some of that capacity back. Without going into the weeds and so forth, what's going on is that [clears throat] the peptide bio regulators are the only substance that I'm aware of that can fix what we call the DNA repair system. And the DNA repair system is built into our cells. It's sort of like you might have an assembly line, you know, where they're putting together some highly technical kinds of things. And on the assembly line, um, there are checkpoints to make sure that all the parts are being put. You'd see this on an automobile, uh, line and so forth. And what happens is that when we were first conceived, this um, DNA repair system is operating at an optimal level. Um and that's why you know 99.9999999% of of cell uh regulation occurs and cell duplication replication occurs and everything you know runs smoothly. Um as we age though this DNA repair system basically starts to kind of deteriorate just for a lot of reasons. Part of it is that the mutations that occur uh you know from the environment from poor food choices and so forth that they damage the assembly line or the the um, the DNA repair system. So what the peptides do u and there's a couple of clinical studies that Cavinson did published that prove this is they go in and they fix the DNA repair system. They return the DNA repair system back to something close to what it was when you were conceived and when you were born. And as a result, when you have a DNA repair system that's functioning as it should, there's a huge cleanup that takes place at the cellular level.

U so we could spend an hour just talking about that, but that's sort of what we've discovered. So I have another question for you for the pineal gland biorereggulator which just for the audience the pineal gland bioore regulator has several different names depending on which form you're we're talking about. So as a whole the pineal gland bioreregulator has an impact on seems to have a positive impact on the immune system. it ac of of its laundry list of benefits that are often cited is that it may upregulate the activity of tomeores which is the enzyme that preserves tieumirs which we're going to talk about in in a little while. It also helps to restore melatonin and it and it restores melatonin to optimal levels rather than boosting it or depressing it. It's looking to normalize. It has a positive impact on the circadian rhythm. There's some studies that Professor Kevinson did that shows that it may have some benefits in the case of cancer which you know I the one I the study I'm most familiar with is a mouse study but there may be others that I I don't know as well and then also talks about being beneficial for cellular oxidative stress when we talk about the bio regulator going like kind of homing in on its home tissue being the pineal gland are all of those impacts being to your knowledge and I don't know if you know the answer to this question but this is one of those burning questions I've always had in my head is all of this happening from the pineal gland acting on those systems oh and also it helps to balance the endocrine system it has a balancing effect on hormones or do you think that there's receptors for that pineal gland bioregulator in other systems like you know I always I always think of it as kind of the master biorereulator but do you have any insight in that or is that still a little bit of one of those things that still needs some clarification and elucidation.

The the latter it needs clarification. We don't really know. Um but it's interesting that [clears throat] when I put together a protocol um and when we're focused on on the two tests that we use as bio in fact let me step back for a minute since it's difficult to make an assessment of overall biological age what we have to use as biomarkers. Um and the biomarkers that uh there are many biomarkers for reflection of biological age but the two that are pretty much predominant are tieumirs and epigenetically or DNA methylation. We know those are uh very much reflective of a person's biological status. Okay. And but there's many other things as well but these are the two that are primary and most importantly these are the two that we can actually do testing on or for you might say right okay so um going back to the question about the pineal gland and so forth we don't know into any depth we don't know how on multiple levels things like the pineal gland peptide how it how it does what it does how how it knows where to go in terms of docking or cleaving and so forth. But what we do know based on Professor Cavenson's studies, extensive studies, is um and I'll have to kind of preface this while we're focused on tieumirs and DNA methylation or epigenetics. If a person in the clinical study has some other organ related issues, you know, they've got some heart history, uh they've got arterial problems, they've got kidney, you know, even some of them, you know, stage three kidney. And by the way, when we first set up the studies, we would accept anyone into the studies pretty much unless they had active cancer. Um but then several years ago as the studies were growing larger and larger we restricted the admission pretty much to physicians and so at that point we could start using the peptides or I should say the physicians would use the peptides uh to deal with various health issues etc like a kidney problem heart problem so when I would put together a protocol focused primarily on longevity um I look at the tieumir situation We test people uh for their tieumir length. Um then the uh epigenetics we we test them for DNA methylation status. But then we would profile what health issues are they concerned about and we would then add appropriate peptides because we have say 21 of those. So we would add relevant peptides. But back to your pineal gland, there is never ever a protocol that we've created that does not include emphasis on the pineal gland and and we don't understand exactly how it does all these amazing things, you know, in the endocrine system and so forth, but it is the prime I would say it's the single most important of the peptides followed only by the thymus peptide.

Yeah. That I call those my desert island peptides.

Yeah. Yeah. [laughter] Yeah.

Although you could argue that if you were on a desert island, maybe you wouldn't even need peptides because you wouldn't have all the horrible things.

Yes. [laughter]

That we're exposed to in the modern world. But a little help never never hurts. Before we launch into the presentation, uh people are going to want to know what are you using to test. I know that you've kind of changed testing companies. We don't need to name names necessarily, but people would love to know probably which test are you currently using to assess people's tieamir length and biological age.

Okay.

Uh DNA methylation, sorry.

Yeah, the tests are are the same. It's just that like anything in the technology uh world, they are enhanced over a period of time. And some [clears throat] labs are are more enhanced than others. uh there are some labs that doing tieumir testing that don't kind of move along with the science as as it has uh progressed and so uh for tieumirs we use a couple of labs that measure the tieumirs on the end of our chromosomes and I'll show some slides that demonstrate that uh we've been using uh a lab since 2012 um but we're now looking at uh we're we're doing beta testing with another lab because we see that their results seem to be much more accurate. Again it's you know you start some of these businesses or labs they start doing things in a certain way and it's very difficult for them to change to something else. So >> for that's the tieumirs for the DNA methylation we've uh used and by the way for the tieumirs uh seven eight years ago longer than that um I beta tested probably six or seven different tieumir testing labs including those in Europe and so forth and when [clears throat] I say uh beta testing I would have the blood samples from the same person sent in over a period of two or three weeks so there would be two or three samples for the same person and I would then look at the results to make sure that they were consistent and the ones that had a large variance of course were were dismissed and so forth. Anyway, so for the DNA methylation, same kind of story. Um, with the DNA methylation, uh, when it first became commercially available about 2020, 2019, there were a couple of labs, uh, that were doing the testing. Um, and but they the the state of the science at that point was that they could only give you a what we call a DNA age. they can measure the DNA methylation and figure out which genes that related to longevity were turned on and turned off and give you that one number. Then about a year later or so, one of the labs um again very progressive people u they were able to divide that up and give us a separate DNA methylation age you might say or or gene related um status of the immune system separately from an overall biological age. And then a couple of years later, about a year later or so, um that particular lab uh partnered with um Harvard and Yale and so forth and they started using very large uh datab banks of of information and using algorithms and they then moved on to where they could give us um their predictions of 11 different organ systems and and so forth. So we could get an overall age, biological age, you could call it epigenetic age, and then we could get uh a predicted age of things like the brain, the pancreas, the heart, the liver, so forth and so forth. So as is true with all technology, it, you know, it develops, it gets better and better. And right now we're beta testing a new company um that's giving us the biological age or epigenetic age of 19 of the systems and organs. And what we are very interested in is that prior to this they were pretty much just giving us predictions. that is the the lab that was doing um this before was able to use the large datab banks and the algorithms used to predict what people's epigenetic age might be for the heart, the liver and so forth. Um this new lab actually doesn't do predictions. It actually does actual measurements uh which is phenomenal. And so I can get a very accurate within a probably about a two-year time span I can get an accurate age for someone's heart. Um in addition and in addition I can uh the information also gives me the pace of aging >> of that heart. In other words, is it is that heart aging faster than the overall body or slower? And so when we create the protocols for for these people, we look at all these and wherever we see accelerated aging pace, then we use more. So if it's say that's a heart that's uh got accelerated aging, it's aging say 10% a year faster than your calendar age, then we use more heart peptides.

Yeah. No, that makes total sense. That's really fascinating. So the the new lab, are they doing tie testing as well or you use a different methodology for that?

Say that again, Natalie.

The new lab, are they are they doing tieumir testing as well or are you using a different lab for that?

Um, oh, we're we're just literally in the process. When I say beta testing, um, [clears throat] whenever I engage a new lab, then it takes months to uh, get the kit test kits, get them out to various people where we're sending multiple kits to the same person as I mentioned earlier, as well as on myself so forth. Um, so it's a process of several months. Um, and we are in the midst of doing beta testing with a new tie lab. Um I'm liking what I'm seeing. Um and we're we've moved on to um this company I I can use the name uh generation labs uh which is the certainly the leader in the world for epigenetic assessment of u the overall system as well as those 19 different um

so you're okay so DNA methylation is generation labs and you're not ready to share the tieumir test yet just because you're still assessing it.

Yeah, until I'm until I'm convinced that that it is more accurate uh than but also let me let me put this in some perspective as when we get into the uh slides. Uh we're going to show um some slides pertaining to reflecting clinical studies where there's significant in fact just like amazing reductions in mortality. Um, and I'll be showing what those uh numbers are and so forth. [sighs] And what we're trying to do overall with people is basically a a makeover, you could call it, of the most significant systems, you know, the epigenetic system, the tieumir system in the body. Um, and you know, while I pay attention to these tests, it's they're not the most important thing. The most important thing is what we're doing is matching what Professor Cavinson was able to do in his multiple year clinical studies. Um, and so even if we didn't do any testing, which I'll explain that in a moment, if someone just took these peptides for a period of three or four years, Professor Cavvenson's research, my experience is they're going to get all of these benefits. Um we primarily use the testing because people like to see um results. Yeah. You know, they like see results that they can actually see on a lab report to show progress. Um and so I have to caution people often times that yes, the lab results are significant. We establish baselines and then we also establish goals uh for the tieumirs and so forth. But really the the program here is to get uh 21 peptide bio regulators out of the boxes and into your body for the next three or four years. And we know the answer is that based on Cavinson's work, we know that that's going to extend your lifespan really significantly and it's going to regenerate organs. And I I have a couple slides that show that it's going to regenerate organs. So, sometimes I'll say it's like a an automobile. Um, you've got this 57 Chevy that I had when I was a kid and [clears throat] it's got tires that have to be renewed periodically. The engine, you know, and the transmission and all that stuff will run a long time, but at some point it all wears out. And what the bio regulators do is with the tieumirs, um, it's like putting on a new set of tires. And I'll explain that with the slides. What the rest of the uh bio regulators do is they go through and they restore everything in the automobile, the engine, the transmission, the computer system and so forth. So that you can drive that car another 50 to 100,000 miles and you know it's difficult to test each of those stages in terms of you know where the where the automobile is in terms of of its assessment you know call it age. Um, so I don't want to spend a lot of time on it, but the tests are helpful, but the really the goal is get a bunch of these peptides into your system over the next three or four years and then go live a long life.

In Professor Kevinson's reports, in those two studies I mentioned earlier, the elderly people study and the old people study, you know, some of the metrics he reports on is better quality of life, better immune system, like they just were healthier in general, they slept better, their bone density was better. He wasn't looking at is your pineal gland healthier. It was like what are the downstream effects? How is this expressing in the person's health? And I know that certainly, you know, in my communities where I've sometimes worked with people with biorereggulators, we sometimes see liver enzymes improve where they were out of balance or how people feel and how they're sometimes we see better blood sugar regulation. They're still doing all the other things, but the bio regulator seems to add another piece to the puzzle as it were. And the last thing I would just want um I wanted to invite you to talk about a little bit before we get into the slides is this idea that of a bio regulator modulating like normalizing function versus boosting function or suppressing function. And this which is part of the reason I think why they're so incredible and it speaks to what they're actually doing because if you're restoring the body's tissues and organs ability to function properly, you're not boosting the immune system, you're not boosting the thyroid, you're not suppressing anything. You're basically laying the work so that the thyroid goes back to working the way it was supposed to or the immune system is working the way it was supposed to.

I should be interviewing you. [laughter]

No, I'm I This is all stuff I learned from you. Are you kidding?

Well, but you just answered the question that you were sort of getting getting close to asking. Yes.

Well, but I'm But you're the guy But you're the guy who worked with Professor Kevinson. [laughter]

[snorts]

You're you're the guy who's done the eight-year [clears throat] study. I'm just dabbling and I'm compared to you. I'm just dabbling. So, what I'm looking for is is this what you've observed as well.

Oh, absolutely. Yeah. Um and we can we can measure, you know, a good amount of that particularly now with the the new DNA methylation stuff. um what the biogs are doing unlike let's say the synthetic peptides which I I think are wonderful actually um the synthetic peptides are giving a a quick boost to whatever the system is or whatever the organ issue is and so forth um and and so they go in it's so like the fire department showing up you know and they're putting out the fire and so okay um the peptides act differently uh they're not going to do anything quickly to start with okay what we know is with the exception of some things like kidney restoration and thyroid restoration. So you're not going to see any feel any or even lab test any real significant changes for about a year. It's a slow process of course to rebuild at the cellular level you know these organs in these systems. So for instance with the tier testing I tell people don't expect to see anything of significance for at least 12 months. Uh with the DNA methylation I tell them two years and that's why we ask people to stay in the clinical studies. We you know it's not a contract but we give them some information and ask them to sign that they've read the information. We tell people stay in this thing for three to four years. Um because that's how long it takes to sort of do this regeneration. It's not a fast process. So

yeah,

should we go to the slides?

I love it.

Let's do it. So for those of you who are listening to this podcast, this would be the part where you might want to hit pause, head on over to your computer, turn on YouTube, and go to somewhere around minute 38 or so, maybe minute 42. And um that's where you're you're going to see the slide presentation. We'll do our best to explain it to you if you don't have the option to do that. But um this is going to get visual. Okay. So here we are. We have the infamous slide presentation up. Let's fire away.

This is uh one of the reasons I went to Russia. I read this study that was published uh about roughly about 2000 so forth. And of course the title caught my attention. You know the mechanisms of peptide regulation of aging. Those words regulation of aging just jumped out at me. And um I started reading everything that I could get my hands on or everything that I could translate and so forth. And I realized that this was for real. I mean this had at that point this had 40 40 years or more of science behind it. And you know I of course did background on Cavinson and learned that he's just you know as bonafide as you can possibly be. As I said earlier well known in Europe well known in pretty much the rest of the world but not here in the US so forth. So this is what uh got me over there. And um so what Cavinson and I did was um this would be about 200 [snorts] oh I don't know 10 or 12 or something in there was I said to him, you know, you've done this amazing work, all of it science-based and so forth. Um everybody knows who you are in Europe and so forth. uh you're unknown in America and unfortunately in America they only pay attention primarily to studies that are based in America or maybe Britain sometimes Israel and so forth. Let's basically do what I call confirming studies in America. Um, let's uh use your uh published studies where you've shown tremen tremendous mortality reduction where you've proven organ regeneration. Let's add to that biological age reversal because cabinson wasn't interested in, you know, call anti-aging at this point. Uh he wasn't focused on it at all. what what he was passionate about was developing new peptides that could be used for mortality reduction and organ regeneration. Um, in fact, he he told me he thought that it was kind of odd the the um the focus that Americans have on anti-aging. He says because you can't have anti-aging. Um, he says you can improve, you know, at the cellular level. You know, he would give me the scientific part of No, he's getting he's kind of getting into semantics like you cannot deage. You can age you can age well, [laughter] right? You can't deage. So, but but he you know we had several discussions. You don't convince people like Cavinson of anything. You give them data. You give them information and they let them decide. I have said several times that he's the most brilliant person scientist I've ever encountered. Um I put him literally in categories with Einstein and some of the other greats. I mean when you see the results that he has produced and so forth it is mindboggling. Anyway so you know gradually he came around to he said to me you know Bill if you if you want to uh do a confirming study u in terms of biological age interventions and so forth then sure let's go ahead and do that and then we'll publish those studies in America and also here in Europe. So that's sort of how this got started in 2017. And we had to figure out, you know, how do we measure biological age and changes in biological age? And and as I we talked about it earlier, uh the the two most trackable uh um interventions would be tor activation and or tie lengthening and DNA methylation. Um and so we use that as our framework to prove that the peptide bio regulators could have a positive impact on biological age. And so this study uh was the one that I ran across that uh was just incredible because what we have going here is in an elderly groups of people we have a significant reduction over a period of years in longevity. Um and as you mentioned earlier when we were talking, it's it's hard to have to do longevity um trials and so forth because people have to live a long time where you can determine if the intervention is been helpful and so forth. But what Cavenson did was over a period of two to six years and then the test uh or the the process continued on for as long as 12 years he [snorts] was able to show very significant reduction in mortality and that's what this um as um this is what the abstract is showing us. So I took the abstract and I basically then created some graphs that would make it easier to understand. And so what we have is there's two groups of people here. The elderly people as they were called in the study and they were that people from 60 to 74 years of age and then the older people down below. Uh Russians are not the most diplomatic calling them old people but um that's now the group I'm in. I'm 7 78 I'll be 79 in two months I guess. So in the group of 60 to 74 year old um the control where it says poly vitamins there in the yellow are the people not on the peptides and if we look at mortality rate in different time frames the mortality rate in 8 years and then drop down where it says 12 years we'll focus on the 12 years. So, it was a 12-ear study. The control group, 44% of those people died. Okay. And that would be normal for that age group over that period of time. Using a you and I were just talking about the pineal gland and and how um um extensive the impact of the pineal gland and the peptides have on the whole body. Notice that in the peptide group using just that one peptide, the mortality rate over 12 years dropped in half. It went from 44% to 22%. I mean, that's unheard of. I mean, that's just there's nothing else out there that I've come across, and I've been at this 30 years now, that will do that.

And then with just one peptide. Okay.

So, we then moved on to the older group uh 75 to 89. And in the control group, the non-peptide group, the mortality rate was basically 82%. You know that for that age group, that part of the world, this by the way was Russia and Ukraine. Um, but using again the pep the pineal gland peptide, it dropped the mortality rate down to 46%, 45.8. But look what happens when a second peptide, the thymus peptide was added. It drops the mortality rate from 82% mortality to 33.

Yeah.

I mean, that's just mindboggling.

And the interesting thing about this, and I I know you know enough of of the history and so forth, and you've read enough of the studies in this uh the old people one, they only use peptides for three years.

Yeah. That's that's you know, that's shocking on the one hand and on the other hand, it makes total sense. Yes, it does.

Right. But but I think one thing that I would like to point out to the audience is that the form of the peptides that they were using here is different than the form that we currently can access in North America. So the pineal gland peptide was epalamin and the thymus was thyolin. And these are actual extracts of those organs of animals that have been prepared for an intramuscular injection. Which is why the poly vitamins is relevant here because everybody was getting an injection of something but nobody knew what they were getting as an injection.

Yes. Uh that is correct. But in the clinical study, we weren't we're not using interuscular. Um

Oh, I get it. But I'm just saying in these studies that's what they were using. And I just think these studies sometimes get misqued quite often because

you know I think what's interesting about the work that you've done now is you've shown that the oral bio regulators the natural biorulators can very effectively in many ways reproduce at least get us in the you know you haven't done the 12ear study the same study that he did but at the same time what you're showing is that those oral bio regulators the natural bio regulators very much produce very powerful results.

Yes, they are. They are the natural extracts in in capsule.

form. And that concerned me a long time ago when we were Cavinson and I were talking about this. And so what Cavinson did was gave me some tie studies that he had run using um the injectables using you know the natural extracts um and or I'm sorry using the synthetics because he had synthetics for uh pitilon and and for the thymus and then using the oral capsules the extracts that I'm using and so over a period of time looking at the tie results using those different methodologies, the difference between the oral natural extracts that we're using and the injectables or the synthetics over a period of several years, a 10% difference. In other words, the oral capsules were 90% as effective in lengthening tieumirs as the injectables or the synthetics.

>> That's amazing. So the synthetics matched up with the oral or did the synthetics match up with the injectable natural?

>> As I recall about halfway in between.

>> Somewhere in between. So then the most the ones that move the needle the most are the natural injectable.

>> Yes.

>> Uh form which is the epialamin and the thyolin. The next in line is the oral natural that is the endolutin.

>> No the next in line is the oral synthetic. oral synthetic.

>> Yeah, there's about six or eight U Kevin has about six or eight of the um peptide regul regulars as synthetics there. We don't use them. They're not used outside of Russia. Um but the synthetic group in the middle uh was less effective than the interuscular but more effective than the natural extracts.

>> Okay. And what about the synthetic like epitalon that the the one the synthetic ones that are that are that are available >> outside of Russia? Have those been studied at all or not so much?

>> Slightly. They're faster acting.

>> Yeah.

>> As any synthetic will be. That's what why the synthetic peptides, you know, that are used like BPC and all the rest of those are very quickly uh used. Um, but if you're looking at longterm, which is what the longevity studies were focused on, if you're looking at long term, you don't want the interuscular, you don't want the six or eight different synthetic uh bio regulators. They're they're good. What you want is to to run the race to the end of three or four years. You want the oil capsules uh in natural extracts.

>> Okay, great. All right.

>> Okay, moving on. So, moving on. Yeah, what this was showing was that previous slide where where Cavins and I, you know, showed that what his work has been all about is mortality reduction. The next part of this is going to be a short one on organ regeneration and then we're going to get to the biological age part.

>> Perfect.

>> Here's the uh the organ regeneration. Um, and in other slideshows I have many of these kinds of things, but no pun intended, but if we're using vision and retina issues, you can kind of see the difference between before, after, and after treatment. And so in all of these uh retinal conditions, diabetic retinopathy, age related macular degeneration, and my favorite, retinitis pigmentotosa, when we're looking at these uh field of vision on the left, where I know the the people listening can't see it, but there's a definite amount of what we call yellow and black occlusions. In other words, where people don't have almost any eyesight where it's uh shown as red and black and so forth where it's shown as green is the vision they have remaining.

>> So um in each of these there is a you know significant amount of red, black and yellow which is impairing people's vision. Um on se several of these on the reinitis pigmentotosa it's almost all black.

>> Yeah. It's incredible.

>> Yeah. And what people tell me um is that if if you're going to have any of these uh retina diseases, you don't want retinitis pigmentotosa. It just closes down. There's nothing that can be done about actually the truthful there's really nothing in the western world that can be done about any of these retinal uh conditions. There's some drops that the opthalmologists use, but basically it's non-reversible in the US, progressive and so forth. So when we look at the screen or the the uh screening field of vision on the right hand side in each of these categories the amount of green which is vision restoration is dramatic. I mean if we look at the diabetic retinopathy I would say there's been a 70 to 80% increase in the green and you know a huge uh decrease in each one of these situations. the macular degeneration, the retinitis pigmentotosa, there's enough improvement that a person I would say on the whole, it's a generalization, but on the whole, a person can have a pretty natural life. I mean, if you look at the diabetic retinopathy, that person probably cannot drive safely a car.

>> On the other hand, after treatment, and the treatment usually lasted two or three years, on the other hand, after two or three years of treatment, they're whizzing around in their car.

>> Yeah. Yeah. 100%. And and and also with the macular degeneration, like not only are you seeing a reversal of the loss of vision, but that means it's it's a double win because you stop the degeneration and you've reversed back to a better state of vision.

>> Absolutely. I mean, it would be it would be enough of an achievement if you could just stop the progression of these diseases and that way because now with the testing you know being able to identify these conditions early on if you could stop the progression I mean, that's amazing.

>> but this situation it isn't just stopping the progression it's reversing it. Yeah, it's incredible. And then the retinitis pigmentotosa, I mean that is a a sentence to blindness. And here we have I mean you know this person still has impaired vision but the increase in the green area is dramatic.

[laughter]

>> So and the problem the issue with reinitus pigmentotosa is that it tends to manifest itself in much younger people.

>> Mhm.

>> It's an inheritable disease. Typically kind of skips a generation and so forth, but many many people are diagnosed in their 20s and 30s.

>> Yeah.

>> Um I I mentioned before and and I'll do it just real quickly. I had two brothers, you know, uh in a family um where there was a history of retinitis pigmentotosa who were diagnosed in the same year in their teens. I think the younger boy was 13 and the older boy was 16. Both of them were diagnosed with retinitis pigmentotosa and that's very very common that it's diagnosed at an early age. Typically it depends you know on each individual case but as a example over about a 10-year period of time from diagnosis they go completely blind. Uh everything is black. Well um through a friend who you know [clears throat] had knew me and knew the family and so forth. Long and the short is we put these boys, this would be 2012. We put these boys on um the vision peptides and and a couple others. We we always use a multiple of peptides and never just one.

>> We put them on the peptides within 6 months their night vision which is impaired um first before other things started improving. 10 years 12 years later uh they have perfect vision. They have they drive cars. They have careers. whereas 10 years later without the peptides they probably would be in utter blackness.

>> Yeah. So are you able to share the peptides that you know the family of peptides that are used in these because it's not just the retina peptides there's there's a couple of and if I'm you know I think that the blood vessel peptide usually plays a role here and our our infamous pineal peptide also seems to play a role in this stack. Am am I right about that?

>> For a condition? Now let's go back to what I was saying earlier that um the the goal is is longevity okay organ regeneration and so forth. So, but we don't ignore conditions that people have. And if the individual primarily about 80% of the people in the clinical study, I think there's about 140 people in the clinical studies, uh, 80% of them are doctors. So, I have a kind of a free hand to be able to create protocols for different medical conditions. And where a person in the clinical study is not a doctor, uh, we then work through their doctor uh, in putting these together. And the norm would be for a condition a minimum of three different peptides typically often times five different peptides. So someone with retinitis pigmentotosa or any retinal disease would have the vision peptide the arterial peptide um the thymus peptide the pioneer gland peptide always in those and those would be probably the four that we would use um for vision uh issues. thymus, pineal, vision, arterial. Yeah, those would be the four that we would have. But because we're doing longevity for these people, the average person on a monthly basis is taking, I would say, five or six, a few people are taking seven different peptides during the course of a month >> because we're, you know, focused on tieumirs and epigenetics, but they're only taking except in a rare case. Well, go back to retinitis pigmentotosa. We would put someone on a highdose protocol for probably about three months. And a high dose protocol would be maybe two capsules a day of each one of those peptides. Sometimes three capsules a day for two or three months and then we'd start graduating down to a lesser uh program. for the people who are just looking at longevity tie DNA um the norm that's used in almost what 90% of the cases is say they're on five different peptides two capsules a day for 10 days only so a total of 10 you know I say 10 10 days only and then off for 20 days >> that's the normal process they're not on unlike American pharmaceutical drugs and so forth where once you go on a drug you're probably on it for the rest of your life.

>> Mhm.

>> And then the whole period is basically about a 3 to four year time frame and then we're done at that point.

>> Back off. Yeah.

>> Do you think you might but over time do you think you might revisit like a maintenance protocol?

>> Well, that's >> after a few years break like would you think about that?

>> That's the problem. That sounds theoretically that sounds like a smart thing and that's what Cavinson and I thought would happen. We figured that at about the three or four year period when we get real close to the goals that we set for these people that uh we would say goodbye to them. Problem is nobody wants to leave.

>> Yeah.

[laughter]

>> Yeah. Literally. So we had to develop a maintenance program. Um I think one person maybe in all these years left. I can't remember why but not disgruntled but Oh no. Yeah. He said he'd check back in 5 years. Um, so we [clears throat] put them on a maintenance program, maybe two different peptides a month, rotating through all of those uh peptides during the year and then we change it for the next year.

>> Yeah. Cool.

>> Okay. So, let's let's move on from this is the organ regeneration. So, this is just a s a summary here. We had 124 participants in this leg or track of the clinical study on different dosages, low, medium, high. And as you noted, I think earlier um there were no other lifestyle changes or interventions. We we didn't tell people to change anything else. We never inquired basically about other things that they were doing, other treatments, lifestyle changes, diet, none of that. We just wanted to the only thing we wanted to do is add the peptides. And this is just a listing of the of the ones that we use the most of. And they're in capsule form. As I say, the normal dosage is two caps a day for 10 days out of the month. So we get to biological reversal which was the goal that I I was focused in in terms of doing these studies and we started with tieumirs because there was testing for tieumirs easily available as blood blood tests 10 or 12 years ago when we started and I won't spend much time on the science of tieumirs but they basically tieumirs are little endcaps on the end of our chromosomes and they're vital for allowing cell replication to occur. her and we know from hundreds last time I checked there were 2500 PubMed U studies and so forth related to tieumirs and uh what we know is that every time we have a cell replication we lose just a little bit of that endcap and while that endcap is intact when we're young cells replicate you know as they should you know the the rep replication goes smoothly and so forth but as we age and as those endcaps deteriorate then you start having problems uh with the quality of the replication and it leads to aging acceleration mortality increases as well as chronic disease.

>> Bill Anders is a well-known scientist here in America and there's a quote here where he says every time our cells divide our tieumirs get a little shorter and every time they shorten our cells age. Um Elizabeth Blackburn was one of three people American scientists who received the Nobel in 2009 and she uh says in this quote that talomer slows the rate at which tieumirs degrade and research indicates people with longer tieumirs have less risk of developing the common illnesses of aging. So that's what tieumirs are all about. So the idea was could we relengthen could we slow the process of tieumir loss and in fact could we relengthen them and so on the screen right now is a study from professor Cson in 2003 um where he shows that the pineal gland peptide induces talomeorous activity we won't go into the mechanics of that basically resulting in tieer lengthening okay

>> y

>> and and that was that was remarkable because slowing ing the loss of tieumirs and and lengthening them is one of the holy grails in all of science and to my knowledge while there are some claims out there um there is no one that can on a consistent basis lengthen tieumirs except the Russians and now of course our clinical study.

>> So what I'm showing next is my results over a period of time. I mean a good scientist I think experiments on himself much like Liz Parish who is is famous for doing and so forth >> and then you start um uh testing on all all of your loved ones and and your friends and you hope that they continue to be your friends and so forth. So um in 2014 this is before I met professor Kevinson it's before I knew anything about really about peptides I was 68 at that time and my first uh tie test showed that my tieumirs were equivalent to someone of a 75 year old in other words when they measure the end of the my chromosomes and look at the tieumirs they can sort of equate that to a bi or to a chronological age so my tieumir age as we called it was 75 or in other My tie were had accelerated loss and I was seven years younger or might you might say older than my um chronological age. Not a good situation for a 68-year-old that accelerated aging.

>> No.

>> Two years later I was uh retested and at that point I had been on the peptides for about a year had met Professor Cavinson so forth. I'm now 70 and at this point my tieumirs are equivalent to a 68-y old. So I've gone from 7 years older tie-wise to two years younger. Two more years later, 2018, I'm 72. My tie age is 44. I've been on the peptides, you know, for about 3 years plus. 2019, I'm 73 chronologically. My tie age was down to 35. And then the most recent test [snorts] um

>> Holy cow, look at you.

>> Yeah. No wonder you look younger.

[laughter]

>> I was I was 76 um at this point and my tie age as we call it was equivalent to a 23 year old male.

>> Amazing. That's really impressive.

>> Yeah. So I I decided to um to decrease the attention on the tieumirs because I was concerned that Vess my wife who who you know was going to leave me for a mature older man.

[laughter]

>> But you could always claim immaturity when you do something that annoys her. You

[laughter]

>> could always say look I mean I'm now 23 the equivalent of a 23y old. We know that the adult male really doesn't mature till what 26 is the current number.

[laughter]

>> I thought it was I thought it was forever.

>> Well, possibly.

>> No, Vess wouldn't buy that anyway.

>> No, I know. I know she wouldn't. She doesn't buy that nonsense. In any event, this is very impressive. So, that was in 20 So, have you tested since 2023 or are you just writing?

>> I'm actually I'm in the process of retesting, beta testing with this new company right now.

>> Oh, wow. Okay. Well, that'll be interesting. When do you expect to get results from that?

>> Uh, four weeks.

>> All right. Well, we'll have to check in with you in September. Yeah, the these lab tests are not like, you know, running down to the local lab and, you know, where they do a a lipid test and so forth and you get the results, you know, two days later.

>> Yeah, they're much more complicated.

>> There's some work to be done. It wasn't just me. Okay. Um,

>> yeah,

[snorts]

>> this is a photo of Torah Bright. to Bright was a three-time Olympic gold and silver competitor uh and was a Olympic gold and silver winner in uh snowboarding, skiing and so forth. And um of course the Olympic doctors I guess they do extensive testing. I I was stunned to find out that they do tie testing but then I understood why >> because we won't spend the time on it today but what we know is that the one one the number one um situation that causes accelerated tieamir loss is stress of all things >> and of course these athletes um to had been you know skiing since she was about five or six years of age and she was now chronologically 32. her doctor, Olympic doctor tested her for tieumirs and her tieumirs were equivalent to a 56 year old woman. Yeah, I think the that you brought I was going to ask you about the stress anyway because that came up earlier in our earlier interviews and I just want to say to the audience because we're going to go long on this podcast that if you take nothing else away from this podcast episode, it's the it's the massive impact the chronic stress that is not dealt with properly will have on your on your pace of a on on your aging really on accelerating your aging at least from telling me our perspective.

>> Yes. In fact, uh Elizabeth Blackburn, who I mentioned earlier, um Nobel Prize and so forth, professor at UC San Francisco, she's done extensive studies on [clears throat] stress and tieumirs. And what they've discovered is that if a woman is pregnant and she's not happy about being pregnant or there are financial issues, uh she's a single uh mother, there's a death of of loved ones in the family, you know, just just a very difficult uh pregnancy. She will give birth to a a newborn on average with 15 to 20% shorter tieumirs at birth than a a woman giving birth where she was happy about having the child. Money wasn't an issue. She's got a supporting spouse, you know, all those kinds of things. It's that powerful that can be passed down >> to an unborn child.

>> Yeah. Well, I mean, you know, there's a lot of talk about generational stress being passed down to a child, and that may be part of it.

>> So, we put >> Yeah, we put to T to about a 18-month program of tieumir bio regulators, and two years later, we retested her. Now, she's two years older at this point, but her tieumirs were equivalent to a 31 year old.

>> Torah wins for the win again.

>> Yeah. So we had u about 120 some odd people and I know that your viewers can't see this but this is one of many many pages of spreadsheets where we track all of this information on the 124 people. So what this spreadsheet is showing a baseline tieumir uh test both in terms of length and age equivalency and then a couple years later uh after we've had the people on the peptide program for a while we do our secondary testing that's the yellow line here and that shows on the whole you know significant timmer lengthening and improvement and then over on the far right the green actually shows the number of years of tie age that we were able to reduce and so we're looking at numbers of 31 years 18 years 19 years reduction or lengthening you might say of tieumirs 14 11 12 but it's interesting because of about 5% or so of the people only get one or two or three years worth of tim lengthening u over multipleyear protocol and we believe because I know knew a lot of these people in the beginning um it has to do with stress in their life. Um, typically the busy business people and so forth or people with with stressful lives ended up receiving less tieumir lengthening. The interesting thing is that [clears throat] every year we lose a little bit of tieumirs but nobody lost a single year in the clinical study even though they were two or three years older.

>> Yeah. Yeah. It's dramatic. I mean, it kind of makes you know, what's interesting is one of the interventions certainly before I heard of biorereggulators one of the few interventions that people believe could help to restore tieumir length is meditation like real meditation being a meditator and a skilled med meditator would be one of those strategies that could help you to manage your stress levels and

>> absolutely

>> and I would think I've never really looked at the studies I'm aware of them I [clears throat] would think that it would be a significant not only for tieumirs but you know for for so many things everything yeah

>> so the the average decrease in what we call cellular or biological age was over a three-year period of time was basically almost 22 years 21.62 62 years. Or in other words, for every 12 months on the program, people were able to lengthen their tieumirs and reduce their tieumir age by about seven years.

>> That's amazing.

>> per year.

>> Beautiful.

>> Okay. Then we got went on to the epigenetic methylation study. Um it became possible to um measure using epig epigenetic um technology. Um, and I'll explain in a moment briefly what epigenetics are all about, but it became possible commercially about 2020. So that's when we added this study. And without going into all the details, it's all about genes that are related to longevity being turned on or turned off. And what we find is that the gene status of genes that are turned on that were are related to helpful with longevity reflects itself in a younger biological age for people. And we know that what affects the the genetics uh of those genes are things like diet, stress, exercise, their sleeping pattern, climate literally neutrauticals, peptides, etc. In other words, everything that we do affects the uh what we call the epigenetics of of gene expression. Uh one person said to me, um it's it's sort of like that the genes are like our [clears throat] computer hard drive and the epigenetics is the software and software can be changed so forth. So that's sort of a short course in epigenetics. The key here is that if you have a younger [clears throat] epigenetic age, in other words, more genes that are related to longevity turned on than off, you basically that will translate into a younger biological age. Uh this just shows, you know, how we do the measurement and so forth. We'll just kind of skip through this. It's based on DNA methylation patterns that that we can actually measure at this point. And what's interesting here is that if you have um a situation where your call it your biological age based on epigenetics, if your epigenetic age is older than your chronological age, uh Dr. Steven Horvith at UCLA and other scientists were able to figure out and report with numerous clinical studies that if your epigenetic age is older than your chronological age, you're in trouble. you've got significant mortality risk over time. And so these are a couple of charts that show the increase in mortality risk based on having an older epigenetic age than a younger. The converse of that is that if your epigenetic age as measured is less than your chronological age, you have a decreased mortality risk. And without going into all the detail in in these slides I show if you're seven years above your chronological age you have an 82% increased mortality risk compared to your same age peers. On the other hand if you're seven years below your uh chronological age you have a 50% decreased mortality risk. So the goal in the clinical study was to make an assessment of people's epigenetic age and then use the peptides at different dosages [clears throat] to uh reduce their epigenetic age. And I know the people can't see the the colors and so forth until they get to YouTube, but the chart that is sort of red raspberry and so forth is the increased mortality risk. The other one that's kind of green and so forth is the decrease. Our goal was to get all the people out of the red into the green >> into the green.

>> Yeah.

>> So, some test results. These are mine mine uh again. So, um but I had I had been on the peptides for about four or five years before this testing became available. And it was uh September of 2020. Uh [snorts] I was 73 years of age at that point, but again had been on the peptides for four or five years. My this lab called it true age. Basically, my epigenetic age was 69 or four years less than my chronological. That translates into about a 28 to 30% reduced risk of all cause mortality. Great place to be on baseline, but again, I've been on the peptides. Most people, particularly Americans that we test as bait lines are 3 to 5 years older than their chronological age, which puts them in an increased mortality risk. So a couple years later, two years later, I retested and I was at that point 75 and uh my epigenetic age was 65. So I was now [clears throat] 10 years less with a significant reduced

>> and um I think my last test I don't think I have it in this set.

>> I'm 21 years younger u than my chronological age epigenetically.

>> That is remarkable. And once again, I'm going to point you guys um the listeners back to one of the earlier episodes where you talk about one of the drivers to you doing this work right at the very beginning and you mentioned it very briefly at the beginning of this podcast is that longevity was not a um quality in your lineage in your family lineage. And uh so people will then understand never mind how impressive these I mean your results are impressive regardless but they become even more impressive when we understand the backdrop of your family history.

>> Yes. Unfortunately uh all the men going back a long long time because we have we do a lot of uh uh research and so forth genealological research they all died in their 50s and 60s all of them. Um, my father had his first heart attack and they all died from heart disease. He had his first heart attack at 57 and died of heart disease at 64 >> and I'm now coming up on 79. So,

>> you're doing all right.

>> Yep. I wake I am grateful every morning when I just wake up and I realize ah I'm breathing again. I get another day.

>> Amazing. And now we have we have someone here who saw some really impressive results.

>> So

>> yeah, what we have here is uh this is Mark, one of the participants. And it's just a sample. I mean, I didn't take the best and so forth, but [snorts] um on his baseline um he his chronological age was basically 63. And uh this is very typical. his intrinsic age as this lab called it which is his uh age epigenetically was basically 70. So he was seven years older which translates to about an 80% increased risk. Two years later uh after being on the program he's uh age now is 64 and a half basically but his epigenetic age has been reduced to 48 years.

>> Yeah. was 16 years younger than his um chronological age.

>> Do you know Mark well? Like does he feel better?

>> Like people will want to know like the test is all fine and dandy, but does he is this showing up at all in his life? Do you know or is that not data that you were necessarily collecting?

>> I wouldn't have access I mean I I talked to these people a lot a lot of emails and text messages and so forth. um it's such a subjective thing. I can say this is that people's labs because the again they're mostly doctors and they share their labs and so their labs um are enhanced significantly and when I ask them how they are doing you know some of these people have now been on the study for seven eight years they say I've never felt better but again it's a subjective thing but what I do hear is that they don't have anywhere near you know most of these most of these people are a great deal of them are 60 to 80 years old. I don't hear about any real medical problems. Once in a while something will come up where, you know, kidney labs will have got deteriorated a little bit, but we get quickly in with the kidney peptides and fix that. Um, but these people are the healthiest group of people that I've ever come across. Um, even they went through COVID and I think probably 5% of the people even just came down with COVID. Um nobody died, nobody had any serious and there were even four or five of the uh individuals who doctors who had to get um um vaccinations in order to be able to practice medicine and so forth. Um so everybody came through the the whole COVID thing intact as far as I know.

>> Amazing. Great.

>> Yeah. So this next slide here is as I said earlier the technology improves and we now can track you know um we can track the immune system independently an overall epigenetic age uh so forth but we also can figure out now what we call a pace of aging. In other words, we can compare a person's biological aging to a standard calendar year aging.

>> Yeah. Um, and so we can determine if you're in a situation where your epigenetic age is accelerating and and you're aging biologically faster than your calendar aging. So this is my results. Again, people can't see this, but in 2020, again, I'd been on the peptides for four or five years. My pace of aging was 0.92. In other words, I was aging each year 8% slower than my calendar aging. In 2021, uh it improved a little bit and I was I was aging 9% slower. 2022, I was aging 11% slower. And my last test, the latter part of this last year, 2024, I was aging at 0.79, which is 21% slower than my calendar aging.

>> Mhm.

>> And that's because of the the peptides.

>> Yeah, exactly. I mean, that's notable.

>> And this [clears throat] one is a kind of a before and after again like Mark. This is someone else um in the program where at their baseline testing he was he was aging 12% faster than his calendar age and then about two years later he was aging 10% slower. So significant turnaround. And I won't go into this one. Natalie, a lot of detail that shows basically over a period of a year huge um in this person.

>> Huge wins, huge huge wins here. I mean, this is a person who started off at a DNA methylation age 9 years older than their chronological and after one year they had now they were now only three years older than their chronological age. So made is that the right person? Am I looking at the right thing?

>> Yeah. No, you're looking at it correctly. Look at the uh what we call the immune age. Um that's that secondary test that they

>> DNA extrinsic. Yeah.

>> He had a really good uh epigenetic immune age, 10 years less than his CH, but then look a year later, he was now 18 years less.

>> Wow.

>> And the other >> and his pace of aging went from 12% faster to 10% slower.

>> Yep.

>> That's a massive delta.

>> Yeah. And I would say this is pretty typical. I'm going to show you in a moment a slide that has the results for the whole 124. But this is, you know, not cherrypicked. This is pretty much what we saw. Um, this is what we call symphony age. The this particular lab, again, technology, you know, advances and so forth. So, what this lab was doing was they were able to then take 11 of the organs and systems and determine an epigenetic age for each one of those 11 systems and chart them. And so the person's uh current age was 63 but they identified that there are 1 2 3 four five six of the organs including his lungs um muscularkeeletal inflammation, kidney and hormone age that were a number of years older than his chronological age. And he had a couple of them that were much younger like his liver was four years younger than his current age. Um, and so we're able to break it down at this point. And this is incredibly helpful to me because when I'm put putting together the protocol based on tieumirs and epigenetics, I can target then for this individual, I would be using more of the lung peptide, uh, the muscularkeeletal, uh, inflammation, so forth, the kidney and so forth,

>> the metabolic, even like the pancreas, the liver.

>> Yeah.

>> All that. Yeah. So it gives me uh some tools that I can be very specific when I'm creating these protocols.

>> Although just one thing that's really interesting to me is that his liver age is is four years younger but his metabolic age is sign it's six years higher >> significantly. Yeah. Yeah.

>> Yeah. Interesting. So uh but now with again you know technology advances and so [snorts] um a lab called generation lab where I'm actually doing the beta testing now um they've you know they have a 25page clinical study peer-reviewed and so forth and they've been doing this for a little while um but I don't take that by itself. I've got to do my own testing uh on

>> but they're giving you an aging a rate a pace of aging by system that's pretty dramatic.

>> It is very >> the last test that was giving you a you know a global pace of aging which is also very helpful but but in terms of targeting your you know your attention on different systems this would definitely give you some insight. It does and again it gets incorporated into the protocols that I uh put together and you know and outside of the peptides of course we have there people having this information can you know do other interventions and be focused elsewhere in terms of what they can do you know in terms of those that are elevated or faster aging. So, there are 19 I know that your audience can't see all this, but there are 19 different systems and organs that they've been able to um determine a epigenetic age of and mark those that are aging at a faster speed than those that are that are younger.

>> Yeah.

>> This person was 44, I think, as I recall. I think it was 44. It was his um chronological age.

>> Is that is this a man? Yes, it's a man.

>> So then why would they get a reproductive system age on ovaries and uterus?

>> Let me take a look and make sure it's a man. Just a second. No, it's not. It has to be a woman

[laughter]

>> because he's pretty remarkable guy.

>> Yeah, he is. No, I just grabbed one of what we call the system age breakdown sheets. I just

>> actually we threw this in this morning as a matter of

>> Well, you know, I'd be curious. I definitely want to have a conversation with these guys because I'd be curious to know on the reproductive system what what they would say on a post-menopausal woman versus a premenopausal woman because postmenopause I don't know how much attent you know I don't know how meaningful it would be that your system age is older. You would think that it would be just by virtue of the fact that it's pretty much you know out of its prime years.

>> Yeah. Um, yeah I'm going to connect you up. I think you're going to find this fascinating. But, you know, this is just how, as we all know, this is how technology works. It just gets more specific and, you know, broader, more detailed, more accurate, and so forth.

>> Um, so we're beta testing this one and and I, if the beta tests turn out the way I think they will, then we're going to be switching our whole system over over to them.

>> Um, so, okay. And so the epigenetic study 124 participants uh the average decrease for the whole group uh in epigenetic age was 4.67 years. Now that doesn't sound very impressive when when we're looking at tieumirs, you know, where you get 20 and so forth and so forth and so forth. But if you're getting a 4.67 six seven uh um what I say epigenetic age benefit based on Horvis work and so forth that can turn into a 50 or 60% I think this one turns into a 56% decrease in all cause mortality risk I'm not aware of anything out there >> that actually can match that

>> yeah no that's pretty dramatic I mean and you know obviously it depends if the person was 10 showing up 10 years older and now they're only 5 years older. You're obviously you're going to be better off if you're below the line, if you're younger than your chronological age, but it's still represents a massive decrease in risk and hopefully gives you the impetus to kind of keep moving so that you can get below that line.

>> Yeah, absolutely. And notice u because this was a more recent clinical study, we we did the cuto off at two years.

>> Mhm.

>> If a person's on it for four years, what's their result going to be? And you're right, the people who are at risk are those who have an older epigenetic age than their chronological. Um, and to be able to reduce that by more than 50% is just really remarkable. So the review of both the tieumir and the DNA methylation or the epigenetic age is that in the tieumirs uh over three-year period of time we were able to lengthen people's tieumirs by almost 22 years and in epigenetically over a 2-year period of time we were able to reduce their epigenetic age significantly but more importantly reduce their um all-c cause mortality risk by 56%. It's pretty sweet.

>> So, this Yep. So, this um slide just shows the kind of what we call current aging expectations. Um the this is how people view aging. You know, they start off as an infinite, you know, young person, middle-aged, and then they start declining and they're frail and so forth. Cavson and I don't believe that this is everyone's fate. We think that with the bore regulators and also when I say the bio regulators you still have to do a lot of other things to be healthy as you and I have talked about you got to clean up the diet and so forth.

>> Um and but this is how professor Cavinson and I see things where a person hits middle age they start getting older and then they clean up their life with bio regulators and diet and all the other technical things that are becoming available and they end up having extended life by 10 or 15 or 20 more years.

>> and healthy years, right?

>> Healthy Oh, that's the important thing, of course. Yeah. It's not just a number of years.

>> Yeah. Exactly. Exactly.

>> So, um I'm going to stop the sharing here.

>> Beautiful.

>> And by the way, we haven't touched on it, but the bio regulars have no adverse side effects. They're natural extracts.

>> 100%. I think that that's a very important point to make. And I think the other important point to make on the bio regulators is um and in a lot of the studies that professor Cavinson did on humans, he was able to show that in the event that people did need medication, the bio-regulators often helped to improve their outcomes even in combination with conventional medications. Like he was not one to throw away the baby with a bath water. like he was definitely of, you know, as a researcher, as a scientist, as a medical doctor and [clears throat] all of those things, he still held alipathic medicine with with some [clears throat] with respect and cuz I just know that I've seen a number of his studies where I think there was a so in particular there's a COPD one where they had a control group, they had the people getting just the medication and then people who got medication and bio-regulators and The people who got the medication and the biorulators actually had a way better outcome than the people who just got the the medication.

>> Absolutely. Uh as you said, he was first and you know at all an MD. That was his training and so forth.

>> And at St. Petersburg at the clinic there, they have besides the research part of it, they have a a clinic where they treat people for you know variety of diseases. um they do not exclude uh medicines you know uh mainline conventional medicines when appropriate.

>> Yeah.

>> So yeah so that's the kind of the coming to the end of the clinical studies. It's been 9 10 years and so forth and we're uh doing now maintenance for the people that are in the clinical studies. [snorts] U but our focus now is is elsewhere. were uh taking the uh peptide program as we call it versus the peptide clinical study and taking it internationally um recently in uh Bali uh Indonesia. Next month we'll be in in uh Dubai. Um and there are individuals and medical clinics and so forth who want to embrace without the restrictions that we have in this country and other countries in terms of [snorts] you know cutting edge things like stem cells and so forth. So we're going to be focusing uh in those markets mostly at the invitation of these uh clinics and things. [snorts]

>> Well that's amazing. That's a beautiful outcome. Do you have now but you know you mentioned that 124 that the line share of the 124 people were physicians who took part in the clinical trial. Have any of those physicians or have all of those physi physicians essentially integrated the bioreulator peptides into their own protocols with their patients or are some of them offering it or do you think you'll ever they'll be sharing that kind of information with people in case people want to have a physician's guidance in in in using bore regulator peptides?

>> Yes. I kind of naively thought that um that many of them if not most of them would be using them for the patients. The reality is that [clears throat] because there's a cost to the peptides, they're not excessively expensive, but there is a cost and so forth. the the patients who have medical issues diagnosed by the physician are the ones that the doctors will of course put them on these peptide protocols because every day I write protocols for uh the doctors you know they'll say I've got a stage three kidney patient and so forth and so I'll write them a protocol but where it didn't expand is that uh the average patient wants their medical problem taken care of but they're not really interested in the longevity I mean if you asked them about it, they said, "Oh yeah, I want to live an old life." Do they want to invest money? You know, because, you know, the cost of these mounts up over three or four years. Um, very few of those people have said, "Oh my goodness, you know, I listened to Lawrence's things and I've listened to you and so forth and I want to live to 100." That happens very rarely. Uh, once their medical issues are taken care of, they're done at that point.

>> Yeah.

>> Yeah. I would say that the audience listening to this episode possibly falls outside of that group of [laughter] people and they'll be clamoring.

>> Nothing wrong with that. I mean, if we have if we've fixed, you know, if we've turned around their liver labs and heart labs and all that stuff, that's wonderful. And and that's maybe all that they're interested in at this point. Um, what we are seeing though is um older wealthy people are getting very focused on they've realized that they maybe have a lot more money than they have years left.

>> And so those are the people that are seeking us out. Um and I as you know we don't do any marketing. Uh I don't have a web page. Um I don't I try and make myself kind of difficult to find >> partly because I'm trying to impersonate u a hermit. Um but also part because I I really want to have balance in my life. Um and I don't want to be overwhelmed. So um the I would say there's a tickling, you know, maybe one a week comes in as we call them concier people, but then I've got this clinic that I mentioned to you in Dubai that's got 30 people lined up for the concier program next month. So [snorts]

>> all right. So the work continues.

>> Yeah. Well, Natalie, it's been a pleasure. It always is fun to talk to you. I had no idea that this was going to last this long though. U hope you can do a lot.

>> Well, you know, we had a a couple of um a couple of little interruptions along the way. So, Dr. Lawrence, this is the part where I usually ask my guests how people can get in touch with them. And as you just explained, you're kind of not in that world right now. So, we're just going to thank everybody for listening and keep your eyes and your ears open. There will be I know that there will be doctors out there and practitioners who and there already are who are leveraging the bio regulators to help their their communities you know and certainly those who are interested just in longevity and others who are interested in moving the needle on certain health challenges that they have. It's already happening and I just think I think it's just going to keep growing. I think that, you know, you're you're really kind of part of a huge piece of the legacy that Professor Cavinson kind of left behind and I'm sure he's smiling and very proud.

>> Yeah, I'm proud to have known him all those years. But one last thing I will say is I know you've got different uh several different groups you know in terms of peptide bio regulators and various things and so forth with your you know because you're not a doctor and you don't need to be to suggest to people you know various peptides that will enhance their health including their liver their you know I know that you have enough knowledge and I think you can you can provide peptides indirectly to people.

>> Yeah. No. And I have been through my through my membership community. For sure. I I run a program there. Sure.

>> No, people should just contact you and let you give them some guidance. I mean, you know, so much about this that you could do a wonderful job and very few of them will be interested in probably the longevity kind of part of, but they want to be, you know, healthier. So, you're the go-to person.

>> Thank you. Well, thank you for that. Here we go.

[laughter]

>> Yes. Okay.

>> Dr. Lawrence, thank you so much for being here and your time and uh generosity. And why don't you come back into the frame for one more second?

>> Oh, okay. Sorry.

>> There we go. Thank you so much. And um I'm looking forward hopefully we'll bump into each other at some point in the not too distant future in real life. Thank you.